| [1] |
Han B F, Zheng R S, Zeng H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4( 1): 47- 53. DOI: 10.1016/j.jncc.2024.01.006. |
| [2] |
National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508. 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508. |
| [3] |
National Health Commission of the People’s Republic of China. Guideline for diagnosis and treatment of primary liver cancer(2026 edition)[J]. J Clin Hepatol, 2026, 42( 4): 794- 827. DOI: 10.12449/JCH260409. 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2026年版)[J]. 临床肝胆病杂志, 2026, 42( 4): 794- 827. DOI: 10.12449/JCH260409. |
| [4] |
Chan S L, Sun H C, Xu Y, et al. The Lancet Commission on addressing the global hepatocellular carcinoma burden: Comprehensive strategies from prevention to treatment[J]. Lancet, 2025, 406( 10504): 731- 778. DOI: 10.1016/S0140-6736(25)01042-6. |
| [5] |
Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73( 6): 1368- 1378. DOI: 10.1016/j.jhep.2020.07.025. |
| [6] |
Fan R, Chen L, Zhao S R, et al. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures[J]. J Hepatol, 2023, 79( 4): 933- 944. DOI: 10.1016/j.jhep.2023.05.039. |
| [7] |
Vitale A, Romano P, Cillo U, et al. Liver resection vs nonsurgical treatments for patients with early multinodular hepatocellular carcinoma[J]. JAMA Surg, 2024, 159( 8): 881- 889. DOI: 10.1001/jamasurg.2024.1184. |
| [8] |
Liu R, Abu Hilal M, Wakabayashi G, et al. International experts consensus guidelines on robotic liver resection in 2023[J]. World J Gastroenterol, 2023, 29( 32): 4815- 4830. DOI: 10.3748/wjg.v29.i32.4815. |
| [9] |
Chiang C L, Chan K S K, Chiu K W H, et al. Complete response to locoregional therapy plus immunotherapy for hepatocellular carcinoma[J]. JAMA Oncol, 2024, 10( 11): 1548- 1553. DOI: 10.1001/jamaoncol.2024.4085. |
| [10] |
Wang Z, Fan J, Zhou S L, et al. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence(CARES-009): A randomised phase 2/3 trial[J]. Lancet, 2025, 406( 10515): 2089- 2099. DOI: 10.1016/S0140-6736(25)01720-9. |
| [11] |
Dong J, Han G, Ogasawara S, et al. LBA2 TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization(TACE) combined with atezolizumab + bevacizumab(Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma(uHCC)[J]. Ann Oncol, 2025, 36: S62. DOI: 10.1016/j.annonc.2025.05.542. |
| [12] |
Kudo M, Ren Z G, Guo Y B, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma(LEAP-012): A multicentre, randomised, double-blind, phase 3 study[J]. Lancet, 2025, 405( 10474): 203- 215. DOI: 10.1016/S0140-6736(24)02575-3. |
| [13] |
Sangro B, Kudo M, Erinjeri J P, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma(EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet, 2025, 405( 10474): 216- 232. DOI: 10.1016/S0140-6736(24)02551-0. |
| [14] |
Yau T, Galle P R, Decaens T, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma(CheckMate 9DW): An open-label, randomised, phase 3 trial[J]. Lancet, 2025, 405( 10492): 1851- 1864. DOI: 10.1016/S0140-6736(25)00403-9. |
| [15] |
Xu J M, Zhang Y Q, Wang G, et al. SCT-I10A combined with a bevacizumab biosimilar(SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial[J]. J Clin Oncol, 2024, 42( 16_suppl): 4092. DOI: 10.1200/jco.2024.42.16_suppl.4092. |
| [16] |
Shi Y H, Han G H, Zhou J, et al. Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma(HEPATORCH): A randomised, open-label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2025, 10( 7): 658- 670. DOI: 10.1016/S2468-1253(25)00059-7. |
| [17] |
Zhou J, Bai L, Luo J, et al. Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma(APOLLO): A randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2025, 26( 6): 719- 731. DOI: 10.1016/S1470-2045(25)00190-1. |
DownLoad: